TLK-199 | Aplastic Anemia and MDS International Foundation


TLK-199 is a small molecule drug that stimulates the bone marrow to produce blood cells.
Brand name: 
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)

Currently TLK-199 is in Phase II of the Food and Drug Administration's (FDA's) clinical trial for the treatment of myelodsyplastic syndromes (MDS).

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.